Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9BWS9
UPID:
CHID1_HUMAN
Alternative names:
Stabilin-1-interacting chitinase-like protein
Alternative UPACC:
Q9BWS9; B3KWB0; Q8NBM9; Q96CZ3; Q96S93; Q96SK0; Q9BY52
Background:
Chitinase domain-containing protein 1, also known as Stabilin-1-interacting chitinase-like protein, plays a crucial role in the immune system. It is known for its saccharide- and LPS-binding capabilities, which are essential in pathogen sensing and endotoxin neutralization. The protein's ligand-binding specificity is influenced by the length of oligosaccharides, showing a preference for chitotetraose in vitro.
Therapeutic significance:
Understanding the role of Chitinase domain-containing protein 1 could open doors to potential therapeutic strategies. Its ability to interact with saccharides and neutralize endotoxins positions it as a key player in the development of treatments for infectious diseases.